Open access
Aug 2026
Impact of Nonmedical Adalimumab Switches in a Rheumatology Patient Population
Background: Adalimumab is an antitumor necrosis factor agent approved by the U.S. Food and Drug Administration in 2002 for the treatment of various rheumatologic diseases. Recent approval of adalimumab biosimilars presents an important area of study to determine real-world efficacy and cost savings of biosimilars. Obje...
S. Delprete, Krista Dessureault, Molly Bachman et al.
· Journal of Pharmacy Technolo... · 0 citations